Targeting aspartate aminotransferase in breast cancer

Breast Cancer Research

Volumn 10, Issue 5, 2008, Pages

  Thornburg, Joshua M ^a   Nelson, Kristin K ^a   Clem, Brian F ^a   Lane, Andrew N ^a   Arumugam, Sengodagounder ^a   Simmons, Allan ^a   Eaton, John W ^a   Telang, Sucheta ^a   Chesney, Jason ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOOXYACETIC ACID; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CYTOSTATIC AGENT; HYBRID PROTEIN; ISOENZYME; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5; OXAMIC ACID; SMALL INTERFERING RNA; TUMOR PROTEIN;

ADENOCARCINOMA; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BREAST TUMOR; CELL DIVISION; CITRIC ACID CYCLE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENETICS; GLYCOLYSIS; HUMAN; MOUSE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ADENOCARCINOMA; AMINOOXYACETIC ACID; ANIMALS; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CITRIC ACID CYCLE; CYTOSTATIC AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; GLYCOLYSIS; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; OXAMIC ACID; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59449083179     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2154     Document Type: Article

References (48)

1. Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, Nathrath W, Schwaiger M. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001, 42:9-16.
2. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000, 83:1688-1695. 10.1054/bjoc.2000.1522, 11104567.
3. Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ, Dang CV. Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res 2000, 60:6178-6183.
4. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007, 67:4182-4189. 10.1158/0008-5472.CAN-06-3184, 17483329.
5. Voet D, Voet J. Metabolism: Glycolysis. Biochemistry. 1995, 444-476. Wiley and Sons, USA, Second.
6. Balinsky D, Platz CE, Lewis JW. Isozyme patterns of normal, benign, and malignant human breast tissues. Cancer Res 1983, 43:5895-5901.
7. Hilf R, Rector WD, Orlando RA. Multiple molecular forms of lactate dehydrogenase and glucose 6-phosphate dehydrogenase in normal and abnormal human breast tissues. Cancer 1976, 37:1825-1830. 10.1002/1097-0142(197604)37:4<1825::AID-CNCR2820370429>3.0.CO;2-V, 177177.
8. Bos R, van Diest PJ, Groep P, Shvarts A, Greijer AE, Wall E. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res 2004, 6:R450-459. 468666, 15217513, 10.1186/bcr813.
9. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994, 269:23757-23763.
10. Nagai MA, Sonohara S, Brentani MM. Estrogen control of lactate dehydrogenase isoenzyme-5 in human breast cancer. Int J Cancer 1988, 41:10-16. 10.1002/ijc.2910410104, 2826342.
11. Nagy I, Hirka G, Kurcz M, Anda E, Baranyai P. The role of estrogens in the regulation of lactate dehydrogenase activity and its submolecular organization in rat anterior pituitary. Endokrinologie 1978, 71:1-12.
12. Markert CL, Shaklee JB, Whitt GS. Evolution of a gene. Multiple genes for LDH isozymes provide a model of the evolution of gene structure, function and regulation. Science 1975, 189:102-114. 10.1126/science.1138367, 1138367.
13. Goldberg EB, Colowick SP. The role of glycolysis in the growth of tumor cells. 3. Lactic dehydrogenase as the site of action of oxamate on the growth of cultured cells. J Biol Chem 1965, 240:2786-2790.
14. Goldberg EB, Nitowsky HM, Colowick SP. The role of glycolysis in the growth of tumor cells. Iv. The basis of glucose toxicity in oxamate-treated, cultured cells. J Biol Chem 1965, 240:2791-2796.
15. Papaconstantinou J, Colowick SP. Published abstract. Federation Proc 1957, 16:230.
16. Papaconstantinou J, Colowick SP. The role of glycolysis in the growth of tumor cells. II. The effect of oxamic acid on the growth of HeLa cells in tissue culture. J Biol Chem 1961, 236:285-288.
17. Cederbaum AI, Lieber CS, Beattie DS, Rubin E. Characterization of shuttle mechanisms for the transport of reducing equivalents into mitochondria. Arch Biochem Biophys 1973, 158:763-781. 10.1016/0003-9861(73)90571-7, 4782532.
18. Greenhouse WV, Lehninger AL. Occurrence of the malate-aspartate shuttle in various tumor types. Cancer Res 1976, 36:1392-1396.
19. Lopez-Alarcon L, Eboli ML. Oxidation of reduced cytosolic nicotinamide adenine dinucleotide by the malate-aspartate shuttle in the K-562 human leukemia cell line. Cancer Res 1986, 46:5589-5591.
20. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005, 102:5992-5997. 1087961, 15840712, 10.1073/pnas.0502267102.
21. Czerniak B, Chen R, Tuziak T, Markiewski M, Kram A, Gorczyca W, Deitch D, Herz F, Koss LG. Expression of ras oncogene p21 protein in relation to regional spread of human breast carcinomas. Cancer 1989, 63:2008-2013. 10.1002/1097-0142(19890515)63:10<2008::AID-CNCR2820631024>3.0.CO;2-D, 2467732.
22. Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET, Green JE. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 2002, 99:6967-6972. 124512, 12011455, 10.1073/pnas.102172399.
23. Miyakis S, Sourvinos G, Spandidos DA. Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun 1998, 251:609-612. 10.1006/bbrc.1998.9527, 9792821.
24. Walker RA, Wilkinson N. p21 ras protein expression in benign and malignant human breast. J Pathol 1988, 156:147-153. 10.1002/path.1711560209, 3058913.
25. Watson DM, Elton RA, Jack WJ, Dixon JM, Chetty U, Miller WR. The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Treat 1991, 17:161-169. 10.1007/BF01806365, 2039838.
26. Taetle R, Rosen F, Abramson I, Venditti J, Howell S. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep 1987, 71:297-304.
27. Wilkinson JH, Walter SJ. Oxamate as a differential inhibitor of lactate dehydrogenase isoenzymes. Enzyme 1972, 13:170-176.
28. Rej R. Measurement of aspartate aminotransferase activity: effects of oxamate. Clin Chem 1979, 25:555-559.
29. Cooper AJL, Meister A. Transaminases 1985, New York: John Wiley and Sons.
30. Fitzpatrick SM, Cooper AJ, Duffy TE. Use of beta-methylene-D, L-aspartate to assess the role of aspartate aminotransferase in cerebral oxidative metabolism. J Neurochem 1983, 41:1370-1383. 10.1111/j.1471-4159.1983.tb00835.x, 6619872.
31. McKenna MC, Waagepetersen HS, Schousboe A, Sonnewald U. Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. Biochem Pharmacol 2006, 71:399-407. 10.1016/j.bcp.2005.10.011, 16368075.
32. Yu AC, Schousboe A, Hertz L. Metabolic fate of 14C-labeled glutamate in astrocytes in primary cultures. J Neurochem 1982, 39:954-960. 10.1111/j.1471-4159.1982.tb11482.x, 6126524.
33. Arai T, Ogawa T, Nakamura M, Hosoya M, Ohnishi Y. Changes in hepatic enzyme activities in transgenic mice carrying human prototype c-Ha-ras gene treated with diethylnitrosamine. J Vet Med Sci 2002, 64:1065-1067. 10.1292/jvms.64.1065, 12499697.
34. Chiaretti B, Casciaro A, Minotti G, Eboli ML, Galeotti T. Quantitative evaluation of the activity of the malate-aspartate shuttle in Ehrlich ascites tumor cells. Cancer Res 1979, 39:2195-2199.
35. Jager J, Moser M, Sauder U, Jansonius JN. Crystal structures of Escherichia coli aspartate aminotransferase in two conformations. Comparison of an unliganded open and two liganded closed forms. J Mol Biol 1994, 239:285-305. 10.1006/jmbi.1994.1368, 8196059.
36. Kamitori S, Okamoto A, Hirotsu K, Higuchi T, Kuramitsu S, Kagamiyama H, Matsuura Y, Katsube Y. Three-dimensional structures of aspartate aminotransferase from Escherichia coli and its mutant enzyme at 2.5 A resolution. J Biochem 1990, 108:175-184. 2121725.
37. Okamoto A, Higuchi T, Hirotsu K, Kuramitsu S, Kagamiyama H. X-ray crystallographic study of pyridoxal 5'-phosphate-type aspartate aminotransferases from Escherichia coli in open and closed form. J Biochem 1994, 116:95-107. 7798192.
38. Smith DL, Almo SC, Toney MD, Ringe D. 2.8-A-resolution crystal structure of an active-site mutant of aspartate aminotransferase from Escherichia coli. Biochemistry 1989, 28:8161-8167. 10.1021/bi00446a030, 2513875.
39. Borisov VV, Borisova SN, Kachalova GS, Sosfenov NI, Vainshtein BK, Torchinsky YM, Braunstein AE. Three-dimensional structure at 5 A resolution of cytosolic aspartate transaminase from chicken heart. J Mol Biol 1978, 125:275-292. 10.1016/0022-2836(78)90403-5, 731696.
40. Borisov VV, Borisova SN, Kachalova GS, Sosfenov NI, Voronova AA. [X-ray-structural study of aspartate transaminase at 5 A resolution]. Dokl Akad Nauk SSSR 1977, 235:212-215.
41. Braunshtein AE, Arutiunian EG, Malashkevich VN, Kochkina VM, Torchinskii Iu M. [Cytosol aspartate aminotransferase from the chicken heart: three-dimensional structure at 2.8 angstroms resolution and the characteristic conformation of various enzyme forms]. Mol Biol (Mosk) 1985, 19:196-208.
42. Ford GC, Eichele G, Jansonius JN. Three-dimensional structure of a pyridoxal-phosphate-dependent enzyme, mitochondrial aspartate aminotransferase. Proc Natl Acad Sci USA 1980, 77:2559-2563. 349441, 6930651, 10.1073/pnas.77.5.2559.
43. Arnone A, Rogers PH, Hyde CC, Makinen MW, Feldhaus R, Metzler CM, Metzler DE. Crystallographic and chemical studies on cytosolic aspartate aminotransferase. Prog Clin Biol Res 1984, 144B:171-193.
44. Jeffery CJ, Barry T, Doonan S, Petsko GA, Ringe D. Crystal structure of Saccharomyces cerevisiae cytosolic aspartate aminotransferase. Protein Sci 1998, 7:1380-1387. 2144045, 9655342.
45. Chesney J, Telang S, Yalcin A, Clem A, Wallis N, Bucala R. Targeted disruption of inducible 6-phosphofructo-2-kinase results in embryonic lethality. Biochem Biophys Res Commun 2005, 331:139-146. 10.1016/j.bbrc.2005.02.193, 15845370.
46. Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res 2007, 67:11284-11290. 10.1158/0008-5472.CAN-07-2728, 18056454.
47. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, Chesney J. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 2006, 25:7225-7234. 10.1038/sj.onc.1209709, 16715124.
48. Wu G, Aoyama C, Young SG, Vance DE. Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. J Biol Chem 2008, 283:1456-1462. 10.1074/jbc.M708766200, 18029352.